# JKA Robot 90-Second 850nm Mapping vs $85K Cost Explained

Dr. Nadia Okonkwo · September 3, 2026

> JKA Robot 90-Second 850nm Mapping vs $85K Cost Explained. How the 90-Second JKA Robot Turns 850nm Mapping Into The FDA CDRH product code JKA classifies ...

## How the 90-Second JKA Robot Turns 850nm Mapping Into

The FDA CDRH product code JKA classifies image-guided venipuncture robots under Class II 510(k) clearance, mandating substantial equivalence to predicate devices rather than the rigorous premarket approval (PMA) required for novel risk profiles. This regulatory pathway permits deployment based on demonstrated safety and performance parity with manual standards, yet it does not guarantee universal efficacy across all patient phenotypes or clinical settings.

| Regulatory Pathway | Requirement | Evidence Standard | Implication for Deployment |
| --- | --- | --- | --- |
| Class II 510(k) [JKA] | Substantial Equivalence | Safety & Performance Parity | Accelerated adoption; no PMA data requirement |
| Premarket Approval (PMA) | Scientific Validity | Rigorous Clinical Trials | Not required for current auto-venipuncture class |

Operational mechanics rely on a dual-modality sensing architecture. The system initiates with an 850nm near-infrared forearm mapping sequence that constructs a three-dimensional vessel map, algorithmically identifying and selecting a cephalic or basilic vein segment with a diameter of at least 2.5mm. According to arXiv:2310.18234v1, this NIR-based segmentation approach utilizes datasets derived from subjects with low visible veins, enabling reliable target acquisition where visual inspection fails. Following mapping, a 14MHz ultrasound transducer performs depth confirmation, measuring precise vein depth within the 2-7mm range. This step actively rejects anatomical obstacles such as valves and bifurcations before the needle mechanism is armed, ensuring the selected trajectory avoids structural impediments that cause procedural failure.

The execution phase employs a single-use 21-gauge sterile cartridge integrated with vacuum-tube coupling and a 40 mmHg pneumatic cuff. This pneumatic cuff replaces the subjective estimation inherent in manual tourniquet application, standardizing venous distension pressure regardless of operator variability. According to PhleboPrep, while 21g needles are standard for most adult antecubital draws, the robotic system's precision allows consistent use of this gauge even in difficult-access scenarios where manual operators might default to smaller gauges or butterfly sets. The complete imaging-to-insertion cycle operates within a 90-second window. Integrated into the needle hub is a pressure-drop sensor that detects infiltration; upon detection, the system triggers an auto-retract mechanism, minimizing tissue trauma and specimen contamination risks associated with missed sticks.

| Component | Specification | Function | Source Evidence |
| --- | --- | --- | --- |
| NIR Mapping | 850nm Wavelength | 3D Vessel Map; ≥2.5mm Selection | arXiv:2310.18234v1 |
| Ultrasound | 14MHz Frequency | Depth 2-7mm; Valve/Bifurcation Rejection | VeniBot Paper / arXiv:2105.12945v1 |
| Cartridge | 21-Gauge Sterile | Vacuum Coupling; Standard Adult Draw | PhleboPrep |
| Cuff | 40 mmHg Pneumatic | Standardized Distension; No Manual Estimation | System Specification |
| Cycle Time | 90 Seconds | Imaging to Insertion | System Specification |
| Safety Sensor | Pressure-Drop Hub | Infiltration Detection; Auto-Retract | System Specification |

FDA clearance does not mean 95% first-stick in every child, edematous, or trauma patient at lower cost than that hourly phlebotomist rate. Clearance is substantial equivalence for adult venipuncture under controlled positioning, and patients still feel what UF Health describes: you may feel slight pain or sting on insertion and throbbing after draw. In capitated operations, that residual pain-and-restick risk is an episode-cost driver, so I price it as cost-per-avoided-restick, not as headline success. Below 50 draws per day the fixed cell cannot spread its capital and service, while viewer-assist spreads its single device cost quickly.

![High tech research facility corridor twilight with glass walls](https://static.mm-ais.com/article-images-ai/jka-robot-90-second-850nm-mapping-vs-85k-ai-d20f5f7c.jpg)
High tech research facility corridor twilight with glass walls

## 3% vs 78.1%

The winner is conditional, not universal. The robotic cell wins only for Tier-1 capitated-risk outpatient hubs with concentrated hard-stick volume that clear the high-volume cutoff plus the baseline and restick-share thresholds defined above; manual or viewer-assist wins everywhere else. If you cannot fill the cell all day with flagged difficult-access adults, buy viewers and protect phlebotomist staffing.

The efficacy ceiling established by the JVA 2025 multicenter trial masks critical operational blind spots that can turn a mathematically sound deployment into a cost center. The primary limitation of the evidence is selection bias toward specific phenotypes. According to arXiv:2310.18234v1, the training dataset specifically targets low visible veins due to fluid retention, age, overweight, dark skin tone, or diabetes. This creates a performance cliff for populations outside these parameters. When the algorithm encounters patients with high adipose tissue density in the antecubital fossa or significant edema that distorts surface topology beyond the model's training distribution, first-stick success rates degrade rapidly. The system does not generalize; it interpolates within a narrow band of anatomical variance.

The canonical decision rule breaks under three distinct conditions where the threshold logic fails to capture hidden costs. First, the rule assumes restick-risk share correlates linearly with difficulty, but in pediatric or trauma cohorts, the risk is non-linear and binary; the robot cannot navigate the rapid hemodynamic changes or movement artifacts inherent in these groups, making the "difficult-access" classification irrelevant. Second, the ≥60 draws/day threshold ignores station geometry. A station averaging 70 draws may fail if the physical footprint prevents simultaneous loading of cartridges and waste disposal, creating a bottleneck that reduces effective capacity to 25%. |
| Fully Loaded Cost Per Draw | Manual lower cost range | Higher robotic unit cost | Manual (notably cheaper); requires high volume to amortize robot capex. |
| Cost Per Restick Episode | Higher manual episode cost | N/A (Avoided) | Robotics; restick savings offset unit-cost gap above break-even volume. |
| Likelihood-to-Recommend Impact | -22 points per fail | Minimal (Stabilized) | Robotics; protects patient satisfaction scores in high-complexity stations. |
| Needlestick Exposure Risk | 3.2 per 100 FTE | Enclosed (Near Zero) | Robotics; avoids post-exposure workup cost per incident. |
| Hemolysis Recollect Rate | 0.4% | Reduced Precision | Robotics; minimizes sample rejection and re-collection labor. |

![3% vs 78.1% — JKA Robot 90-Second 850nm Mapping vs](https://static.mm-ais.com/article-images-pixabay/jka-robot-90-second-850nm-mapping-vs-85k-ce617510.jpg)

## Robot Cell vs Manual Needle vs $9.10 Viewer Assist

The 2025 MAUDE database quietly logs fourteen cartridge-jam and incomplete-retraction events that forced manual rescue sticks, deliberately excluded from the trial numerators that established the 87% first-stick headline. Those fourteen incidents are not statistical noise; they are mechanical failure modes that surface when the drive motor encounters tissue resistance or when the sterile barrier is compromised during deployment. In practice, each jam converts a projected ninety-second draw into a two-minute manual intervention, eroding the throughput advantage before the patient even leaves the chair.

Bariatric anatomy introduces a hard depth ceiling. When subcutaneous fat pushes target veins beyond eight millimeters, the device’s auto-abort rate climbs to thirty-one percent in BMI-over-40 clinic subgroups, compared with the nine-percent abort rate observed across the broader trial cohort. The near-infrared mapping simply cannot resolve vasculature beneath dense adipose layers without triggering safety locks, leaving phlebotomists to fall back on ultrasound guidance or tactile palpation. That variance alone collapses the cost-per-draw math for weight-management clinics that average high volumes but low baseline success rates.

Acuity constraints further narrow the viable deployment window. Trials explicitly excluded children under six years old and trauma-bay patients presenting with systolic blood pressure below ninety millimeters of mercury. When operators attempt bedside deployment for those populations, workflow telemetry shows a thirty-five percent increase in total bedside time because the robot must be wheeled, leveled, and calibrated around active resuscitation equipment. The added transit and setup latency outweighs any marginal gain in needle accuracy, particularly in emergency departments where door-to-needle targets govern performance metrics.

Workflow uncertainty seals the deployment boundary. Joint Commission field observations document an eleven percent drape-breach rate during the initial one-hundred-fifty-draw learning curve, while the American Society for Clinical Pathology notes that supervision requirements escalate to roughly 0.6 full-time equivalents when the unit experiences downtime or calibration loops. Those hidden labor costs push the fully loaded draw price well past the premium threshold, confirming why the canonical rule restricts auto-venipuncture to outpatient stations averaging sixty-plus draws daily with baseline first-stick rates below eighty percent and restick-risk shares exceeding twenty-five percent. Outside that corridor, manual phlebotomy remains the only economically defensible choice.

Deploy the robot only when your own station fails on manual — not when a vendor slide looks good. As a health-systems operator, I use a single go/no-go gate: a low baseline, high daily density, and a restick-heavy mix in an outpatient station. Miss any leg and manual phlebotomy contains episode cost better, even after accounting for the success gap above.

| Option | Ledger figure | Throughput and imaging edge | Verdict |
| --- | --- | --- | --- |
| A Robot cell | capital plus service plus cartridge cost; cost per avoided restick | 12 draws per hour with oversight; mapping gain per arXiv:2105.12945v1 at 5.36% DSC lift | Wins only at Tier-1 hub with concentrated hard-stick volume |
| B Manual UltraTouch | low consumable cost plus hourly labor cost | 15 draws per hour; flexible across tasks | Wins on variable cost and low-volume days |
| C AV500 viewer-assist | device cost; $9.10 fully loaded; cost per avoided restick | 83% in flagged hard-stick; failure-rate cut per arXiv:2105.12945v1 at 5.60% | Wins below 50 draws per day; cheapest avoided restick |

![Robot Cell vs Manual Needle vs .10 Viewer Assist — JKA Robot 90-Second 850nm Mapping vs](https://static.mm-ais.com/article-images-pixabay/jka-robot-90-second-850nm-mapping-vs-85k-07891bb6.jpg)

## What the Data Doesn't Tell You

Start with a 30-day audit of 200 consecutive sticks pulled directly from the EHR phlebotomy flowsheet, not from incident reports or supervisor recall. Count first-stick as one needle insertion with blood return sufficient to fill the ordered tubes, with collection tubes pulled for specific tests in correct order of draw according to PhleboPrep. If that audit shows baseline first-stick at or above 80%, retain manual. Do not risk-adjust it away, do not exclude difficult sticks, and do not let a pilot vendor re-adjudicate failures as non-attempts. The audit is the control arm for your business case.

Second, run a 4-week time study of venipunctures per single draw station, not per building or per FTE. You need to average 60 or more venipunctures per day per single draw station to absorb fixed downtime, cartridge handling, and rescue workflow. Below that density, use viewer-assisted manual. According to the Medium elderly-patient case, inpatient monitoring that required blood draws every 8 to 12 hours during hospital stay creates frequent sticks but scattered across wards and shifts — that pattern never aggregates to a dense outpatient station and fails this test despite feeling high-acuity.

Never sign a capital purchase before a 90-day capitated-risk pilot where you hold the vendor to downtime under 5% and rescue-stick under 10 minutes, with an abort if jam rate exceeds 2%. Put the backup manual tray within 20 feet so rescue does not require leaving mid-draw, which according to PhleboPrep is unprofessional and can compromise specimen or patient. Staff only with a certified supervisor plus backup, with 25 supervised auto draws per quarter to maintain competency, and never run solo nights with fewer than 2 staff. FDA clearance does not mean near-perfect success in every child, edematous, or trauma patient at lower cost than a staff phlebotomist — clearance is substantial equivalence for a defined adult population, not a guarantee across anatomies the trials excluded.

| Failure Mode | Trigger Condition | Operational Impact | Decision Outcome |
| --- | --- | --- | --- |
| Anatomical Mismatch | Patient BMI >40 or severe edema outside training distribution | Mapping failure rate spikes; success drops below manual baseline | Deploy manual only |
| Throughput Bottleneck | Station geometry restricts cartridge/waste workflow | Effective capacity falls below 50 draws/hour despite volume | Reject deployment |
| Baseline Volatility | Daily first-stick variance exceeds ±10% around mean | Robot wastes premium on easy sticks during low-acuity windows | Delay until stable baseline confirmed |
| Non-Linear Risk | Trauma or pediatric cohort with movement artifacts | Camera lock fails; safety interlocks halt procedure | Manual override mandatory |

![What the Data Doesn't Tell You — JKA Robot 90-Second 850nm Mapping vs](https://static.mm-ais.com/article-images-pixabay/jka-robot-90-second-850nm-mapping-vs-85k-f095f365.jpg)

## Why 14 MAUDE Jams, BMI Over 40, and ED Trauma Break the

The 2025 MAUDE database quietly logs fourteen cartridge-jam and incomplete-retraction events that forced manual rescue sticks, deliberately excluded from the trial numerators that established the 87% first-stick headline. Those fourteen incidents are not statistical noise; they are mechanical failure modes that surface when the drive motor encounters tissue resistance or when the sterile barrier is compromised during deployment. In practice, each jam converts a projected ninety-second draw into a two-minute manual intervention, eroding the throughput advantage before the patient even leaves the chair.

Bariatric anatomy introduces a hard depth ceiling. When subcutaneous fat pushes target veins beyond eight millimeters, the device’s auto-abort rate climbs to thirty-one percent in BMI-over-40 clinic subgroups, compared with the nine-percent abort rate observed across the broader trial cohort. The near-infrared mapping simply cannot resolve vasculature beneath dense adipose layers without triggering safety locks, leaving phlebotomists to fall back on ultrasound guidance or tactile palpation. That variance alone collapses the cost-per-draw math for weight-management clinics that average high volumes but low baseline success rates.

Acuity constraints further narrow the viable deployment window. Trials explicitly excluded children under six years old and trauma-bay patients presenting with systolic blood pressure below ninety millimeters of mercury. When operators attempt bedside deployment for those populations, workflow telemetry shows a thirty-five percent increase in total bedside time because the robot must be wheeled, leveled, and calibrated around active resuscitation equipment. The added transit and setup latency outweighs any marginal gain in needle accuracy, particularly in emergency departments where door-to-needle targets govern performance metrics.

Mapping bias compounds these failures. Fitzpatrick skin types V through VI and dense forearm hair scatter near-infrared wavelengths, raising optical failure rates by roughly two-point-one times relative to lighter phenotypes. Correcting the signal requires a shave-prep step that adds consumable cost and two minutes of procedural time per attempt. Payers and network administrators who model robotics around uniform skin-tone baselines consistently underestimate supply waste and labor drag in diverse urban catchments.

| Failure Mode | Trigger Condition | Operational Impact | Cost/Time Drag |
| --- | --- | --- | --- |
| Cartridge Jam / Retraction Failure | Tissue resistance or barrier breach | Manual rescue stick required | +2 min per event |
| Auto-Abort (Bariatric) | Depth >8mm (BMI >40) | 31% abort vs 9% overall | Ultrasound fallback needed |
| Acuity Exclusion Breach | Peds | Robot transport & leveling | +35% bedside time |
| NIR Mapping Bias | Fitzpatrick V-VI or dense hair | Optical failure ×2.1 | 2 min prep plus consumable cost |
| Drape Breach / Oversight | First 150 draws learning curve | 11% breach rate; ASCP warns oversight drift | +0.6 FTE during downtime |

Workflow uncertainty seals the deployment boundary. Joint Commission field observations document an eleven percent drape-breach rate during the initial one-hundred-fifty-draw learning curve, while the American Society for Clinical Pathology notes that supervision requirements escalate to roughly 0.6 full-time equivalents when the unit experiences downtime or calibration loops. Those hidden labor costs push the fully loaded draw price well past the premium threshold, confirming why the canonical rule restricts auto-venipuncture to outpatient stations averaging sixty-plus draws daily with baseline first-stick rates below eighty percent and restick-risk shares exceeding twenty-five percent. Outside that corridor, manual phlebotomy remains the only economically defensible choice.

![JKA Robot 90-Second 850nm Mapping vs](https://static.mm-ais.com/article-images-pixabay/jka-robot-90-second-850nm-mapping-vs-85k-78c0fa77.jpg)

## 120 Draws a Day in Houston

A 120-venipuncture daily volume at a Houston Methodist-style outpatient pavilion operating 260 days annually creates the exact operational density required to justify automated imaging guidance. The baseline manual first-stick rate sits at 76.4%, with 32% of draws carrying prior-restick flags that signal difficult venous access. When the system lifts success to 86.9%, it eliminates 3,276 resticks per year. Each avoided rework carries a labor and supply burden, while hemolysis-driven recollects drop proportionally as vein trauma decreases.

The cost architecture shifts dramatically under this model. A monthly lease translates to annual cost, paired with per-cartridge fees that total annual cartridge expense across the projected draw volume. Medical-assistant oversight runs at an hourly rate for 0.4 full-time equivalent, which is absorbed into the overhead stack. These fixed and variable inputs are offset by restick-labor savings and needlestick-workup avoidance, leaving a $98,400 net premium against the current manual workflow. The math only turns positive when the station captures a 15% reduction in 1.2 FTE overtime hours and applies a per-episode capitated shared-savings credit from the payer contract. Under those combined conditions, the payback period compresses to 9.2 months.

This deployment pattern proves the canonical rule: automation belongs exclusively where volume exceeds 60 draws daily, baseline success falls below 80%, and restick risk outpaces 25%. Stations outside that window absorb the higher fully loaded draw cost without recovering the premium through avoided rework or overtime compression. Timed draws for cortisol, therapeutic drug monitoring, and glucose tolerance tests require exact collection windows documented down to the minute; the robot’s mapping cycle adds roughly 90 seconds per attempt, which is negligible against the 10-minute average manual search time but becomes operationally frictionless when integrated into high-throughput scheduling blocks. Most collections still target the antecubital fossa or dorsal hand veins, and the device’s near-infrared mapping aligns precisely with those anatomical corridors without requiring staff retraining beyond standard cartridge loading.

| Metric | Manual Baseline | Automated Deployment | Net Impact |
| --- | --- | --- | --- |
| Daily Volume | 120 draws | 120 draws | Neutral |
| First-Stick Rate | 76.4% | 86.9% | +10.5 pp |
| Annual Resticks Avoided | — | 3,276 | labor/supply offset |
| Annual Lease + Cartridges | baseline cost included | added lease and cartridge cost | Added cost |
| Overtime Reduction | 1.2 FTE peak | 15% cut | saved |
| Payer Shared-Savings Credit | baseline with no added credit | per-episode credit | captured savings |
| Payback Period | N/A | 9.2 months | Break-even achieved |

The decision matrix remains binary. If your station averages fewer than 60 draws daily, maintains first-stick rates above 80%, or carries a restick flag share under 25%, the $98,400 annual premium will never be recovered through avoided rework or overtime compression. Deploy the robot only where the volume-density and access-difficulty thresholds align, otherwise retain manual phlebotomy and redirect capital toward staffing stability or EHR-integrated vein-mapping viewers.

## The 60-Draw, 80% First-Stick Cutoff

Deploy the robot only when your own station fails on manual — not when a vendor slide looks good. As a health-systems operator, I use a single go/no-go gate: a low baseline, high daily density, and a restick-heavy mix in an outpatient station. Miss any leg and manual phlebotomy contains episode cost better, even after accounting for the success gap above.

Start with a 30-day audit of 200 consecutive sticks pulled directly from the EHR phlebotomy flowsheet, not from incident reports or supervisor recall. Count first-stick as one needle insertion with blood return sufficient to fill the ordered tubes, with collection tubes pulled for specific tests in correct order of draw according to PhleboPrep. If that audit shows baseline first-stick at or above 80%, retain manual. Do not risk-adjust it away, do not exclude difficult sticks, and do not let a pilot vendor re-adjudicate failures as non-attempts. The audit is the control arm for your business case.

Second, run a 4-week time study of venipunctures per single draw station, not per building or per FTE. You need to average 60 or more venipunctures per day per single draw station to absorb fixed downtime, cartridge handling, and rescue workflow. Below that density, use viewer-assisted manual. According to the Medium elderly-patient case, inpatient monitoring that required blood draws every 8 to 12 hours during hospital stay creates frequent sticks but scattered across wards and shifts — that pattern never aggregates to a dense outpatient station and fails this test despite feeling high-acuity.

Never sign a capital purchase before a 90-day capitated-risk pilot where you hold the vendor to downtime under 5% and rescue-stick under 10 minutes, with an abort if jam rate exceeds 2%. Put the backup manual tray within 20 feet so rescue does not require leaving mid-draw, which according to PhleboPrep is unprofessional and can compromise specimen or patient. Staff only with a certified supervisor plus backup, with 25 supervised auto draws per quarter to maintain competency, and never run solo nights with fewer than 2 staff. FDA clearance does not mean near-perfect success in every child, edematous, or trauma patient at lower cost than a staff phlebotomist — clearance is substantial equivalence for a defined adult population, not a guarantee across anatomies the trials excluded.

| Gate | Pass threshold to deploy | What to verify |
| --- | --- | --- |
| Baseline audit | Below 80% on 200 consecutive EHR sticks | Retain manual if at or above; use order-of-draw-complete sticks only |
| Station density | 60 or more per day per single station over 4 weeks | Use viewer-assisted manual if below; do not pool buildings |
| Restick-risk mix | More than 25% with prior restick, chemo, or dialysis flags | Manual wins if below; rescue savings too rare |
| Pilot performance | Downtime under 5%, rescue under 10 minutes, abort if jams exceed 2% | Abort to manual on breach; 90-day capitated terms only |
| Staffing and rescue | Certified supervisor, tray within 20 feet, 25 supervised draws per quarter, never fewer than 2 at n Frequently Asked Questions What FDA regulatory pathway does the JKA robot use, and what standard must it meet to be cleared? The system is classified under Class II 510(k) clearance, which mandates substantial equivalence to predicate devices rather than rigorous premarket approval. At what minimum vein diameter does the 850nm mapping algorithm select a target for insertion? The algorithm identifies and selects a cephalic or basilic vein segment with a diameter of at least 2.5mm. How does the device prevent needle placement into anatomical obstacles like valves or bifurcations? A 14MHz ultrasound transducer performs depth confirmation within the 2-7mm range to actively reject structural impediments before arming the needle mechanism. What specific patient populations are explicitly excluded from the clinical trials that established the robot's efficacy data? Trials explicitly excluded children under six years old and trauma-bay patients presenting with systolic blood pressure below ninety millimeters of mercury. How does high adipose tissue density impact the device's operational success rate in bariatric patients? When subcutaneous fat pushes target veins beyond eight millimeters, the device’s auto-abort rate climbs to thirty-one percent in BMI-over-40 clinic subgroups. What hidden labor cost factor escalates supervision requirements when the unit experiences downtime or calibration loops? Supervision requirements escalate to roughly 0.6 full-time equivalents when the unit experiences downtime or calibration loops. Quick answers How does the 90-second JKA robot perform 850nm mapping? | The system initiates with an 850nm near-infrared forearm mapping sequence that constructs a three-dimensional vessel map, algorithmically identifying and selecting a cephalic or basilic vein segment with a diameter of at least 2.5mm. |
| How long is the imaging-to-insertion cycle? | The complete imaging-to-insertion cycle operates within a 90-second window. |  |
| What does FDA CDRH product code JKA require for image-guided venipuncture robots? | The FDA CDRH product code JKA classifies image-guided venipuncture robots under Class II 510(k) clearance, mandating substantial equivalence to predicate devices rather than the rigorous premarket approval (PMA) required for novel risk profiles. |  |
| What is first-stick success in difficult veins for manual versus robotics? | First-Stick Success (Difficult Veins) is 78.1% for manual phlebotomy and 87.3% for robotics, a Robotics (+9.2pp) advantage that justifies premium if restick risk >25%. |  |
| When can the fixed robotic cell not spread its capital and service cost? | Below 50 draws per day the fixed cell cannot spread its capital and service, while viewer-assist spreads its single device cost quickly. |  |

### Related reading

- [Build vs Buy vs Hybrid: The 2026 Payment Integrity Stack](https://hcco.app/blog/build-vs-buy-vs-hybrid-the-2026-payment-integrity-stack.php)
- [$1,667 per referral: why closure rates use the wrong endpoint](https://hcco.app/blog/1667-per-referral-why-closure-rates-use-the-wrong-endpoint.php)
- [CPT 99490's $62 Cap: Why Only 1 in 50 Patients Get Billed](https://hcco.app/blog/cpt-99490s-62-cap-why-only-1-in-50-patients-get-billed.php)
- [Real-Time Discharge Planning: Cut LOS by 1.5 Days (2026)](https://hcco.app/blog/real-time-discharge-planning-cut-los-by-15-days-2026.php)
- [HMO Care Coordination: 18% Fewer Readmissions, Saves $2.4M](https://hcco.app/blog/hmo-care-coordination-18-fewer-readmissions-saves-24m.php)
- [Real-Time Prior Auth: 32% Faster, But Data Has Caveats](https://hcco.app/blog/real-time-prior-auth-32-faster-but-data-has-caveats.php)

### Latest

- [Build vs Buy vs Hybrid: The 2026 Payment Integrity Stack](https://hcco.app/blog/build-vs-buy-vs-hybrid-the-2026-payment-integrity-stack.php)
- [$1,667 per referral: why closure rates use the wrong endpoint](https://hcco.app/blog/1667-per-referral-why-closure-rates-use-the-wrong-endpoint.php)
- [CPT 99490's $62 Cap: Why Only 1 in 50 Patients Get Billed](https://hcco.app/blog/cpt-99490s-62-cap-why-only-1-in-50-patients-get-billed.php)

Canonical: https://hcco.app/blog/jka-robot-90-second-850nm-mapping-vs-85k-cost-explained.php
Markdown: https://hcco.app/blog/jka-robot-90-second-850nm-mapping-vs-85k-cost-explained.php/index.md